Milena Anatchkova
Overview
Explore the profile of Milena Anatchkova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim C, Brown F, Burk C, Anatchkova M, Sargalo N, Kaushik A
Qual Life Res
. 2024 Mar;
33(5):1373-1387.
PMID: 38438664
Purpose: To identify symptoms and their impacts on daily functioning and health-related quality of life (HRQoL) experienced by adult patients with ulcerative colitis (UC) and evaluate patient-reported outcome (PRO) measures...
2.
Burden A, Bissonnette R, Anatchkova M, Budhiarso I, Skalicky A, Liberato A, et al.
J Eur Acad Dermatol Venereol
. 2024 Feb;
38(7):1383-1390.
PMID: 38334243
Background: Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease associated with considerable patient burden. The Psoriasis Symptom Scale (PSS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and...
3.
Smith M, Gaglio B, Anatchkova M
Health Res Policy Syst
. 2024 Jan;
22(1):17.
PMID: 38287407
Background: The uptake, adoption and integration of new medicines and treatment regimens within healthcare delivery can take a decade or more. Increasingly, implementation science (IS) research is being used to...
4.
Burden A, Bissonnette R, Lebwohl M, Gloede T, Anatchkova M, Budhiarso I, et al.
J Eur Acad Dermatol Venereol
. 2023 Mar;
37(7):1327-1335.
PMID: 36854864
Background: Generalized pustular psoriasis (GPP) is a rare and life-threatening skin disease often accompanied by systemic inflammation. There are currently no standardized or validated GPP-specific measures for assessing severity. Objective:...
5.
Auchus R, Courtillot C, Dobs A, El-Maouche D, Falhammar H, Lacroix A, et al.
Front Endocrinol (Lausanne)
. 2022 Dec;
13:1005963.
PMID: 36465641
Background: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare autosomal recessive condition characterized by cortisol deficiency and excess androgen production. The current standard of care is...
6.
Lenderking W, Anatchkova M, Pokrzywinski R, Skalicky A, Martin M, Gelhorn H
J Patient Rep Outcomes
. 2021 Jul;
5(1):61.
PMID: 34283357
Background: There has been a growing emphasis on health-related quality of life (HRQoL) as an important outcome in rare disease drug development, although its assessment may be useful outside the...
7.
McHorney C, Mansukhani S, Anatchkova M, Taylor N, Wirtz H, Abbasi S, et al.
PLoS One
. 2021 Mar;
16(3):e0248240.
PMID: 33705486
Background: Heart failure is rising in prevalence but relatively little is known about the experiences and journey of patients and their caregivers. The goal of this paper is to present...
8.
Armstrong A, Edson-Heredia E, Naegeli A, Burge R, Poon J, Anatchkova M, et al.
J Dermatolog Treat
. 2019 Jun;
31(5):452-459.
PMID: 31157576
Psoriasis is a chronic inflammatory skin disease. To establish content validity and assess psychometric properties of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis (Ps). The PSS is...
9.
Anatchkova M, Brooks A, Swett L, Hartry A, Duffy R, Baker R, et al.
Int Psychogeriatr
. 2019 Mar;
31(9):1305-1318.
PMID: 30855002
Objectives: More than 90% of individuals with Alzheimer's disease (AD) experience behavioral and neuropsychiatric symptoms (NPS), such as agitation. However, little is known regarding the specific burden of agitation for...
10.
Anatchkova M, Donelson S, Skalicky A, McHorney C, Jagun D, Whiteley J
J Patient Rep Outcomes
. 2018 Dec;
2(1):64.
PMID: 30588562
Background: To explore the existing evidence of the real-world implementation of patient-reported outcomes (PROs) in oncology clinical practice and address two aims: (1) summarize available evidence of PRO use in...